依普利酮对高血压有多大疗效呢？

It is a new type of selective aldosterone receptor antagonist and an antihypertensive drug. It has the characteristics of strong selectivity for aldosterone receptors, good antihypertensive effect, and long-lasting effect. It can reverse or reduce many adverse effects of aldosterone on cardiovascular disease. So, how effective is eplerenone on hypertension?

The therapeutic effect of eplerenone in treating hypertension:

Eplerenone was approved for clinical use by the State Food and Drug Administration in 2002. It has a stronger antagonizing effect on aldosterone than spironolactone, and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. It is a good alternative to spironolactone.

For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction.

Furthermore, the FDA has approved eplerenone (Inspra - Pfizer) for use in stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and congestive heart failure after acute myocardial infarction (MI) to improve survival. Eplerenone is the first aldosterone receptor blocker approved for this indication.

The FDA's approval was based on the results of the EPHESUS (Eplerenone Efficacy and Survival Study in Heart Failure After Acute Myocardial Infarction) trial. In patients with heart failure after myocardial infarction, eplerenone plus standard care reduced mortality by 15% compared with placebo and standard care (ACE inhibitors and beta-blockers). EPHESUS was published in the April 2003 issue of the New England Journal of Medicine.

The above is the relevant content about the therapeutic effect of treating high blood pressure!